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Summary Bone mineral density (BMD) and content (BMC) were measured in 208
institutionalised patients with refractory epilepsy. BMD was in the osteoporotic range
in 43% of males and 21% of females. BMC was reduced only in male patients. Apart
from age and gender, no other factor or specific AED was particularly associated with
reduced BMD or BMC. This study indicates the magnitude of the problem of bone
disease in refractory epilepsy, in particular affecting young and male patients with
chronic epilepsy.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Epilepsy is associated with an increased fracture risk
two to six times that of the general population with
about 40% of fractures directly related to seizures.1
Antiepileptic drugs (AED) have negative effects on
bone mineral density (BMD) and concentration
(BMC) through a variety of mechanisms, the most
significant thought to be an increased rate of bone
turnover.2 The AEDs most commonly associated with
bone disease are inducers of the cytochrome P450* Corresponding author at: Department of Clinical and Experi-
mental Epilepsy, Institute of Neurology, University College
London, 33 Queen Square, London WC1N 3BG, United Kingdom.
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doi:10.1016/j.seizure.2007.03.003enzyme system,3 but this is not the sole cause of
AED-induced osteopathy. The non-enzyme inducing
AEDs do not confer any protection over BMD.4
Further, epilepsy may be associated with other
factors that result in reduced BMD, such as immo-
bility. We determined the prevalence of osteoporo-
sis and the factors associated with reduced BMD in
patients with chronic epilepsy within a longer-term
care facility.Methods
Bone densitometry was performed in 208 patients
(145 male) with a median age of 45 years (range:
20—86 years). Distal radius BMD and BMC were
measured by dual energy X-ray absorptiometry. Published by Elsevier Ltd. All rights reserved.
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Table 2 Summary of antiepileptic drugs tried at pre-
sent and in past and median duration of treatment
Patients (%) Median (months)
Carbamazepine 86 168
Phenytoin 74 96
Valproate 71 96
Lamotrigine 58 39
Phenobarbitone 51 120
Primidone 33 108
Topiramate 32 12
Oxcarbazepine 28 17
Ethosuximide 28 12
Levetiracetam 28 12
Gabapentin 20 6
Acetazolamide 19 12(DXA). This forearm region is affected minimally by
degenerative changes compared with the spine.5
Calcium, 25(OH)-vitamin-D, parathyroid hormone
(PTH) and AED levels were measured routinely.
Previous and current AED therapy, fractures and
wheelchair dependency were ascertained from
the medical notes. Statistical analysis was carried
out in SPSS 11.0. Unpaired T-tests and Mann—Whit-
ney U-tests were used where appropriate. Multiple
regression was used to determine significant con-
tributing factors to absolute BMD and logistic regres-
sion to determine which covariates increased the
odds of having BMD T-score in the osteoporotic
rather than normal range.Tiagabine 13 15
Table 3 Bone mineral density (BMD), content (BMC),
T and Z scores; range, mean and standard deviation
(S.D.)
Mean Range S.D.
Absolute BMD 0.46 0.21 to 0.69 0.09
Absolute BMC 3.50 0.86 to 5.79 0.84
BMD T-score 1.85 5.5 to +1.7 1.56
BMD Z-score 1.10 5.1 to +2.1 1.43
BMC T-score 1.03 3.9 to +2.9 1.42
BMC Z-score 1.01 3.9 to +2.9 1.38Results
There was no difference in age, BMI and clinical
parameters between genders (Table 1). The popula-
tion had a high fracture risk with 67% of patients
having a history of fractures and 54% of patients
having at least one fracture since admission.
AED treatment
Only one patient had started treatment with AEDs
after reaching the age of peak skeletal bone mass.
Four patients had only ever tried one AED, all others
had tried at least two up to 17 AEDs (median number
of AEDs tried: 7). The number of current regular
AEDs ranged from 0 to 5 with amedian of 2. Only two
patients were currently not on AEDs. Thirty-nine
patients were on monotherapy, and the remainder
were on polytherapy with two AEDs (n = 79), three
AEDs (65), four AEDs (16), or five AEDs (2). Most of
the patients (86%) had been treated with carbama-
zepine (Table 2).
BMD and BMC
According to the WHO definition, 65 patients (31%)
were osteopaenic (1.1 < T-score < 2.49) and 76
patients (37%) were osteoporotic (T < 2.5). The
prevalence of osteoporosis was greater among menTable 1 Summary of demographic data (median and range
Male (n = 145)
Age (years) 46
BMI 25
Length of admission (years) 17
Duration of epilepsy (years) 37
Age of epilepsy onset (years) 6.5
Wheelchair bound (%) 23
BMI, body mass index.(43%) than women (21%). Age and gender corrected
BMD Z-scores were significantly lower in patients
than in the normal population (Z: 1.10; p  0.001)
(Table 3). Men (BMD-Z:1.42; p  0.001) weremore
affected than women (BMD-Z: 0.36; p = 0.004).
Patients’ BMC Z-scores were significantly lower than
that of the normal population (Z: 1.01;
p = 0.0001), but this was only significant for men
(Z: 1.42; p = 0.0001), not for women (Z: 0.1;
p = 0.43).
Prior to DXA scans, seven patients were treated
with bisphosphonates. Four of those seven patients
were osteoporotic, and three had normal T-scores. A
further 12 patients were on vitamin-D/Ca supple-
mentation. Of those 12 patients, 5 were osteoporo-
tic, 3 osteopenic and 4 had normal T-scores.) of 208 patients
Female (n = 63) Range (total)
46 20—86
26 19.4—34.1
17 0.5—70
38 8—78
6.0 0—37
15
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affect the results of the above comparisons.
Biochemistry
Biochemical data were comparable between gen-
ders, apart from PTH (females: 5.38 pmol/l versus
males: 2.57 pmol/l; p = 0.04) Six patients (all
female) had raised PTH (>8.5 pmol/l). Three
patients had vitamin-D deficiency (25-OHD <
10 ng/ml) and33patients hadvitamin-D insufficiency
(10 ng/ml < 25-OHD < 20 ng/ml). There was neither
significant correlation between vitamin-D levels and
history of fractures, nor between BMD and vitamin-D
or PTH levels.
Osteoporosis (T-score < 2.5) versus
normal BMD
Patients with osteoporosis (n = 76; median age 55
years) were significantly older than patients with
normal BMD (n = 67; 41 years; p  0.001). The osteo-
porotic group had significantly longer duration of
epilepsy. There was no significant difference in BMI,
age of epilepsy onset or AED history between osteo-
porotic and normal groups for eithermale or female.
Wheelchair dependency did not relate to BMD or
BMC. Although a higher proportion of osteoporotic
patients had sustained one or more fractures com-
pared with patients with normal BMD (56% c.f. 48%)
this was not significant (p = 0.33).
Using simple linear regression analysis adjusting
for age and gender, there was a significant negative
association between BMD with age of onset
(B = 2.77  103, S.E. = 0.001, p = 0.024, multiple
correlation coefficient R = 0.47). There was no sig-
nificant association between age of onset and BMC,
and no association between either BMD or BMC and
other variables.
Using logistic regression, being male was asso-
ciated with a five-fold increase in odds of osteo-
porosis compared with females, and every year
increased the odds of osteoporosis by 4%. No other
variable was a significant contributor in this analy-
sis.
AED treatment: osteoporosis versus
normal BMD
Effect of enzyme inducers
Only 11 patients had never been treated with known
enzyme inducers, and their BMD- and BMC Z-scores
were not different from the remainder. There was
no difference between patients (n = 60) never trea-
ted with phenytoin, primidone or phenobarbitone,
and patients (n = 148) exposed to any of these threeAEDs. Univariate analysis of variance, correcting for
age and sex, did not reveal any association between
BMD and duration of various AEDs. Of the 39 patients
on monotherapy, 25 were on carbamazepine or
oxcarbazepine, 7 on phenytoin, 3 on lamotigine, 2
on valproate and 1 each on levetiracetam and topir-
amate. Analysis was limited by the small numbers of
the individual therapies, but there was no signifi-
cant difference between BMD Z-scores in patients on
carbamazepine/oxcarbazepine monotherapy and
phenytoin, or between carbamazepine/oxcarbaze-
pine monotherapy and other monotherapy.
Effect of enzyme inhibitors
Treatment in the past or present with a known
enzyme inhibitor was not associated with higher
BMD- or BMC Z-scores.
Effect of new AEDs
Patients prescribed the ‘‘new AEDs’’ (e.g., lamotri-
gine, topiramate, oxcarbazepine, levetiracetam,
gabapentin and tiagabine) were significantly
younger than patients not on new AEDs (new AED:
43 years versus old AED: 55 years; p  0.001). BMD-
and BMC Z-scores were not different between
patients who had been treated for more than 6
months with a new AED (n = 135) and those
(n = 73) never treated with these AEDs.Discussion
In our population of institutionalised patients with
refractory epilepsy, BMD was significantly reduced
compared to the normal population. In contrast to
the normal population, male patients had twice the
risk of osteoporosis than females. The group with
osteoporosis was older, as expected. Every year was
associated with a 4% increase in risk of osteoporosis.
Except for gender and age, no other contributing
factors could be isolated. No specific AED, nor type
of AED such as enzyme inducer or inhibitor, old or
new, significantly increased the risk of osteoporosis.
There was no difference between those treated with
phenytoin, phenobarbitone and primidone, and
those never treated with these drugs. The newer
AEDs were prescribed to a significantly younger
population and for a shorter duration, and thus,
their long-term effects cannot be compared with
the older agents.
Our results are contrary to other studies.6 The
enzyme inducing AEDs most commonly associated
with bone disease were not found to be associated
with lower BMD, BMC or vitamin-D levels. A poten-
tially bone sparing effect of acetazolamide was
reported in women,7 suggesting that newer, less
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mate or zonisamide)might have a similar effect. Our
findings for topiramate or acetazolamide are not
more favourable than for the other AEDs and a more
recent study associated acetazolamide with
increased bone loss.6
Our cross-sectional audit does not allow to sepa-
rate the effects of duration of epilepsy and long-
term AED treatment. The number of AEDs tried over
the years correlated with the duration of epilepsy
and age of the patients. The negative association
between age of epilepsy onset and BMD but not BMC
is difficult to explain. It is possible that patients who
started AEDs around puberty had the worst affected
bone growth, and thus lower BMD but not BMC, as
this is mineralization rather than growth.
Our data analysis is complicated by many factors
contributing to osteoporosis, such as institutionali-
sation and immobility. Patients had been in residen-
tial care on average for 17 years and 20% were
wheelchair-dependent, which generally increases
the incidence of reduced BMD.2 Serial biochemistry
measurements rather than single snapshots would
have been more useful in the analysis of their
relationship with bone density. BMD and BMC take
longer to change and reflect a couple of years of
bone turnover. Other factors known to be associated
with osteoporosis were not surveyed, such as con-
current medication other than AED, and smoking
history.
The peripheral scanner used has many advan-
tages, such as portability, cost and simplicity of
use, but it is a screening, not a diagnostic tool with
forearm measurements correlating only moderately
with hip and poorly with spine BMD.8 However ver-
tebral fractures have been associated with
decreased BMD at the distal radius, and distal fore-
arm BMD has enabled the prediction of future frac-
tures of the hip in postmenopausal women, although
the predictive power is not as strong as BMD mea-
surements at the hip itself.9 In postmenopausal
women the pattern of bone loss is more global
whereas wheelchair use reduces predominantly
hip BMD, and this might explain why we did not find
a correlation between immobility and forearm BMD.
Nevertheless, our findings are consistent with a
recent study showing reduced BMD in the femoralneck in epileptic patients irrespective of whether
they had been treated with enzyme inducers or non-
inducers.10Conclusion
Our findings support the hypotheses that AED treat-
ment may have negative effects on BMD particularly
aggravated in male patients and by other factors
related to institutionalisation. A further audit is
required to assess the benefits of regular screening
and prophylactic supplementation with vitamin-D
and calcium.References
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